952429-83-3

Upstream product

• 952429-82-2 [(2S,3R,4R,5S,6R)-2-Allyloxy-5-benzyloxy-6-hydroxymethyl-4-(4-methoxy-benzyloxy)-tetrahydro-pyran-3-yl]-carbamic acid 2,2,2-trichloro-ethyl ester 

Downstream Products

• 952429-84-4 1-propenyl 6-O-allyloxycarbonyl-4-O-benzyl-2-deoxy-3-O-(4-methoxybenzyl)-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside 
• 958248-97-0 6-O-allyloxycarbonyl-4-O-benzyl-2-deoxy-3-O-(4-methoxybenzyl)-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranosyl trichloroacetimidate 
• 952429-88-8 allyl 4-O-benzyl-6-O-(6-O-allyloxycarbonyl-4-O-benzyl-2-deoxy-3-O-(4-methoxybenzyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl)-2-deoxy-2-((R)-3-(4-trifluoromethylbenzyloxy)octadecanoylamino)-α-D-glucopyranoside 

Relevant academic research and scientific papers

Synthesis of immunoregulatory Helicobacter pylori lipopolysaccharide partial structures

The synthesis of immunoregulatory glycoconjugates, namely the active entity of lipopolysaccharide (LPS) from Helicobacter pylori was achieved. The results of biological activities of the LPS partial structures provide the structural basis for the immunobi